2023年WHO全球结核病报告：全球与中国关键数据分析

doi:10.19871/j.cnki.xfcrbzz.2023.06.014

摘要/Abstract

摘要： 据估算,2022年全球新增结核病患者1060万例,中国新增病例数为74.8万例（占全球发病数的7.1%）,在30个结核病高负担国家中排第3位;全球结核病死亡人数约130万例,中国结核病死亡数估算为3万例;2022年,全球有约41万例耐多药/利福平耐药结核病患者,中国约有3万例。2015–2022年结核病发病率累计下降8.7%,死亡人数净减19%,仍有约49%的结核病患者及其家庭面临灾难性支出,与世界卫生组织终止结核病策略所确定的2025年阶段性目标存在较大差距。2018–2022年全球累计治疗3400万例结核病患者,累计有1550万例患者接受预防性治疗,未能实现2018年联合国结核病问题高级别会议制订的五年宣言目标。2022年全球结核病诊治服务复苏,全球新诊断并报告结核病患者750万例,为1995年WHO监测全球结核病数据以来的最高值,然而通报数与估算数间仍然存在有约310万例的差距。2020–2022年间全球结核病发病率上升了3.9%,要早日实现全球终止结核病策略目标,亟须将2023年9月第二次联合国结核病问题高级别会议上重审的承诺转化为实际行动。对标全球数据,中国仍然面临结核病及耐多药/利福平耐药结核病负担重等严峻现实,建议采取多部门联合行动、加快实现全民健康覆盖、提升卫生系统服务能力及加强科学技术创新。

关键词: 结核病, 报告, 终止结核病策略, 数据分析

Abstract: An estimated 10.6 million people fell ill with tuberculosis worldwide in 2022, and there were 748 000 total cases in China(accounts for 7.1% of global cases). China ranks the third out of 30 high tuberculosis burden countries. The estimated tuberculosis deaths of Worldwide were 1.3 million, and China were 30 000. Globally, an estimated 410 000 people developed multidrug-resistant or rifampicin resistant TB (MDR/RR-TB) in 2022,these figures in China were 30 000. Globally, the cumulative reduction in the TB incidence rate from 2015 to 2022 was 8.7%, the net reduction of deaths was 19%, and 49% of TB patients and their households face total costs that are catastrophic, far from the 2025 milestones of WHO End TB Strategy. The cumulative number of people treated between 2018 and 2022 was 34 million, 15.5 million people were treated with TB preventive treatment. The global target set at the 2018 UN high-level meeting on TB has not been achieved. The global TB services were recovering in 2022. Globally in 2022, 7.5 million people were newly diagnosed with TB and officially notified as a TB case, with the services were recovering. This is the highest number since WHO began global TB monitoring in 1995. However, there was still a global gap about 3.1 million cases between the incident cases and the notified cases. The TB incidence rate is estimated to have increased by 3.9% between 2020 and 2022. The global termination of TB strategy should be achieved early and achieve ending the global TB epidemic requires that the new and reaffirmed commitments made at the second UN high-level meeting on TB in September 2023 are urgently translated into action. With the global data to set the standard, China still faces the grim reality of the high burden of TB and MDR/RR-TB. It advise to take the multisectoral action, accelerate the achievement of universal health coverage, improve the capacity of health systems, and strengthen scientific and technological innovation.

Key words: Tuberculosis, Report, The end tuberculosis strategy, Data analysis

中图分类号:

卢春容, 谭卫国, 陆普选, 王豪朋. 2023年WHO全球结核病报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2023, 8(6): 73-78.

Lu Chunrong, Tan Weiguo, Lu Puxuan, Wang Haopeng. 2023 WHO Tuberculosis Report: key data analysis for China and the global world[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(6): 73-78.

参考文献

[1] 中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288-2017)[J/CD]. 新发传染病电子杂志,2018,3(1):59-61.
[2] MAKAM P, MATSA R."Big Three" Infectious Diseases: Tuberculosis, Malaria and HIV/AIDS[J]. Curr Top Med Chem, 2021, 21(31):2779-2799.
[3] GBD 2019 DISEASES AND INJURIES COLLABORATORS. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019BD 2019 DISEASES AND INJURIES COLLABORATORS. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258):1204-1222.
[4] WORLD HEALTH ORGANIZATION. Cause-specific mortality, 2000-2019[EB/OL]. [2020-12-9]. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death.
[5] WORLD HEALTH ORGANIZATION.Global tuberculosis report 2023[EB/OL]. [2023-11-07]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023.
[6] WORLD HEALTH ORGANIZATION.Global tuberculosis report 2022 [EB/OL]. [2022-10-25]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.
[7] WORLD HEALTH ORGANIZATION.Global tuberculosis report 2021[EB/OL]. [2021-10-14]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.
[8] WORLD HEALTH ORGANIZATION. Global tuberculosis report1997[EB/OL]. [1997-06-23]. https://iris.who.int/bitstream/handle/10665/63354/WHO_TB_97.225_(part1).pdf?sequence=1.
[9] 余卫业,谭卫国,罗一婷,等. 2018 WHO全球结核报告:全球与中国关键数据分析[J/CD].新发传染病电子杂志,2018,3(4):228-233.
[10] 任坦坦,邓国防,付亮,等. 2020 WHO全球结核报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志,2020,5(4):280-284.
[11] 卢春容,房宏霞,陆普选,等. WHO 2021年全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志,2021,6(4):368-372.
[12] MADDALENA C, MARGHERITA B, SEAN W, et al.Safety implications of combined antiretroviral and anti-tuberculosis drugs[J]. Expert Opin Drug Saf, 2020, 19(1):23-41.
[13] UNITED NATIONS.Sustainable development goals[EB/OL]. [2020-07-20].https://sustainabledevelopment.un.org/topics/sustainabledevelopmentgoals.
[14] FLOYD K, GLAZIOU P, HOUBEN R, et al.Global tuberculosis targets and milestones set for 2016-2035: definition and rationale[J]. Int J Tuberc Lung Dis, 2018, 22(7):723-730.
[15] WORLD HEALTH ORGANIZATION. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update[EB/OL]. [2021-07-05]. https://iris.who.int/handle/10665/342331.
[16] WORLD HEALTH ORGANIZATION. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment, 2022 update[EB/OL]. [2022-12-15]. https://iris.who.int/handle/10665/365308.